Consolidated net sales for the Human Vaccines business in the nine months to end September were up 28.3% at euro 2,129 million. Over the period, net sales of Menactra(R) rose by 89.0% to euro 344 million, and net sales of Adacel(TM) were 69.2% higher at euro 195 million.
Change on 2007 Change on
2007 Q3 a 9-month a
net comparable net comparable
euro million sales basis sales basis
Polio/Pertussis/Hib Vaccines 147 -14.0% 518 +6.6%
Adult Booster Vaccines 113 +43.0% 332 +35.5%
Meningitis/Pneumonia Vaccines 190 +95.9% 397 +66.8%
Travel & Other Endemics Vaccines 88 +11.4% 251 +13.1%
Influenza Vaccines 365 +117.3% 521 +37.5%
Other vaccines 40 +5.3% 110 +22.2%
TOTAL 943 +49.2% 2,129 +28.3%
Third-quarter sales at Sanofi Pasteur MSD, the joint venture with Merck & Co in Europe, advanced by 79.2% on a reported basis to euro 324 million, buoyed by the success of Gardasil(R) (net sales of euro 101 million).
Gardasil(R), the first vaccine against papillomavirus infections (which cause cervical cancer) is marketed by Sanofi Pasteur MSD in 19 European countries. To date, Gardasil(R) is funding in 9 European countries.
For the nine months to end September, Sanofi Pasteur MSD reported net
sales of euro 669 million, an increase of 43.1% on a reported basis. Net
sales of Gardasil(R) totaled euro 182 million over this period. Sanofi
Pasteur MSD sales are not consolidated by sanofi-aven
Copyright©2007 PR Newswire.
All rights reserved